Masimo (NSDQ:MASI) met Wall Street’s forecast for its full-year and 4th-quarter earnings, giving its shares a 2% bump yesterday and sending them another 3% higher today.
The Irvine, Calif.-based patient monitoring systems maker reported profits of $$13.8 million, or 23 cents per share, on sales of $112.3 million for the 3 months ended Dec. 31, 2011, for a top-line increase of 6.4% but a bottom-line decline of 14.2%, compared with Q4 2010.
Mela Sciences (NSDQ:MELA) announced an expanded 3-year manufacturing contract with long-time supplier Askion GmbH for production of the MelaFind devices.
MelaFind, the company’s flagship product, is a handheld, non-invasive melanoma detection and identification system designed to help a physician decide whether or not to biopsy a suspect patch of skin.
Group purchasing organization Premier said it signed a raft of supply deals for a variety of medical device products.
The Charlotte-based GPO said it signed deals for endomechanical, trocar, suture and topical skin adhesives with 16 companies.
Group purchasing organization Novation inked a deal with Cook Medical for its supply of central venous catheters.
The contract includes Cook’s line of comprehensive CVC products, including its Spectrum minocycline and rifampin impregnated catheters, used to reduce the risk of catheter-related bloodstream infections.
Zimmer Holdings (NYSE:ZMH) shares are down this morning in early trading after the orthopedics giant lowered its sales and earnings guidance for 2011 – despite beating analysts’ expectations with its third-quarter earnings.
Warsaw, Ind.-based Zimmer said third-quarter profits were $192 million, or $1.01 per share, on sales of $1.03 billion for the three months ended Sept. 30, up 5.2 percent and 6.9 percent, respectively, compared with the same period last year.
Hologic Inc. (NSDQ:HOLX) reported growth in sales and booming earnings its third quarter ended June 25, driven by increased revenues in its breast health sector, which includes its 3D mammography system.
Breast health revenues grew 8 percent to $205 million, compared to $189 million during the same period last year.
ConMed Corp. is suing a former sales rep and rival Champion Orthopaedics Inc., alleging that they conspired to poach customers from the University of Massachusetts hospital system.
ConMed Corp. (NSDQ:CNMD) posted fourth-quarter sales of $179.2 million for the three months ended Dec. 31, 2009, down 6 percent compared with $190.6 million during the same period in 2008. Net income rose 67.9 percent to $8.3 million, compared with $5 million during Q4 2008:
CONMED Corporation Announces Fourth Quarter and Full Year 2009 Results
Fourth Quarter Sales Increase 6.4%